NCT01026194View on ClinicalTrials.gov

Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Placebo / Teneli (Teneligliptin) + pio (pioglitazone)

Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone.

DRUG

Teneli / Teneli + pio

Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone.

Trial Locations (1)

Unknown

Shinjukuku

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY